# Changelog
## Multiple Myeloma Biomarker Discovery Project

All notable changes and project milestones are documented in this file.

---

## [Phase 1: Clinical Analysis] - 2026-01-30 ✅ COMPLETE

### Added
- **Clinical Data Analysis Pipeline**
  - Patient-level data processing (7,185 → 995 patients)
  - Kaplan-Meier survival curves by ISS stage
  - Cox proportional hazards regression (multivariate)
  - Age-stratified survival analysis
  - Gender-specific survival analysis
  
- **Publication-Quality Figures** (6 total)
  1. `km_survival_by_iss_stage.png` - Main survival curves with 95% CI
  2. `patient_characteristics_panel.png` - 4-panel demographic summary
  3. `age_stratified_survival.png` - Survival by age groups
  4. `cox_regression_hazard_ratios.png` - Forest plot of hazard ratios
  5. `gender_survival_analysis.png` - Male vs Female comparison
  6. `patient_characteristics.csv` - Summary statistics table
  
- **Data Processing**
  - `patient_level_clean.csv` - Clean dataset (995 rows, 12 columns)
  - `clinical_merged.csv` - Merged raw data
  - Data validation and quality control
  
- **Documentation**
  - `README.md` - Professional project overview with key findings
  - `METHODS_AND_RESULTS.md` - Comprehensive methodology and results
  - `KEY_FINDINGS.md` - Quick reference summary for applications
  - `CHANGELOG.md` - Project history (this file)

### Key Findings
- **ISS staging is the dominant prognostic factor**
  - Stage II vs I: HR = 1.74 (p = 0.018) ✅
  - Stage III vs I: HR = 1.75 (p = 0.013) ✅
- **Age and gender are not independent predictors**
  - Age: p = 0.772 ❌
  - Gender: p = 0.621 ❌
- **Median survival by stage**
  - Stage I: 22.3 months
  - Stage II: 15.4 months
  - Stage III: 14.9 months

### Statistical Methods Implemented
- ✅ Kaplan-Meier survival curves
- ✅ Log-rank testing (p = 0.023)
- ✅ Multivariate Cox regression
- ✅ Hazard ratio calculations with 95% CI
- ✅ Stratified analysis (age, gender, ISS)

---

## [Phase 2: Documentation & Polish] - 2026-01-30 ✅ COMPLETE

### Added
- Professional README with badges and structured sections
- Comprehensive METHODS_AND_RESULTS documentation
- KEY_FINDINGS quick reference guide
- CHANGELOG to track project evolution

### Improved
- Project structure organization
- Documentation clarity and completeness
- Code comments and docstrings
- Notebook organization with clear sections
- Requirements file with all dependencies

### Repository Structure
```
myeloma-biomarker-project/
├── notebooks/          # Analysis notebooks
├── src/               # Reusable Python modules
├── data/              # Raw and processed data
├── results/           # Figures, tables, models
├── docs/              # Documentation files
├── README.md          # Main project description
├── CHANGELOG.md       # This file
└── requirements.txt   # Python dependencies
```

---

## [Phase 3: RNA-seq Integration] - PENDING 🚧

### Planned Features
- [ ] Download RNA-seq data from GDC (787 patients with expression data)
- [ ] Differential expression analysis by ISS stage
- [ ] Identify genes correlated with survival outcomes
- [ ] Gene signature development (supervised learning)
- [ ] Pathway enrichment analysis (GSEA)
- [ ] Integrate clinical + genomic predictors
- [ ] Build machine learning models (Random Forest, Cox-ElasticNet)
- [ ] External validation on independent cohort
- [ ] Generate new notebook: `02_genomic_biomarker_discovery.ipynb`

### Expected Deliverables
- Gene expression heatmap (top prognostic genes)
- Volcano plot (differential expression)
- Survival-gene correlation matrix
- ML model performance metrics (AUC, C-index)
- Integrated clinical-genomic risk score
- Additional 4-5 publication figures

---

## [Phase 4: Advanced Modeling] - FUTURE 📅

### Planned Features
- [ ] MGUS → MM progression analysis
- [ ] Treatment response prediction
- [ ] Multi-omics integration (RNA + DNA mutations + CNV)
- [ ] Deep learning survival models
- [ ] Interactive Shiny/Plotly dashboard
- [ ] Manuscript preparation for publication

---

## Project Timeline

| Phase | Description | Duration | Status |
|-------|-------------|----------|--------|
| **Setup** | Project structure, data download | 1 day | ✅ Complete |
| **Phase 1** | Clinical analysis | 1 day | ✅ Complete |
| **Phase 2** | Documentation | 1 day | ✅ Complete |
| **Phase 3** | RNA-seq integration | 2-3 days | 🚧 Pending |
| **Phase 4** | Advanced models | 1 week | 📅 Future |

**Total Time to Date:** 3 days  
**Lines of Code:** ~1,500+  
**Figures Generated:** 6  
**Statistical Tests:** 15+

---

## Technical Details

### Software Versions
- Python: 3.8+
- pandas: 2.2.3
- numpy: 1.26.4
- matplotlib: 3.9.3
- seaborn: 0.13.2
- lifelines: 0.29.0
- scipy: 1.13.1
- statsmodels: 0.14.4

### Data Versions
- MMRF CoMMpass: Release 23 (GDC)
- Clinical data: Downloaded 2026-01-30
- Patient count: 995 (after QC)

### Reproducibility
- All code in Jupyter notebooks (`.ipynb`)
- Random seeds set where applicable
- Environment captured in `requirements.txt`
- Git version control enabled
- Data processing pipeline documented

---

## Contact & Acknowledgments

**Project Author:** [Your Name]  
**Institution:** [Your University]  
**Program:** PhD Application - Cancer Bioinformatics  
**Date:** January 2026

**Data Source:**  
Multiple Myeloma Research Foundation (MMRF)  
CoMMpass Study (NCT01454297)  
Accessed via NCI Genomic Data Commons

**Funding:** Not applicable (educational project)

---

## License

MIT License - See LICENSE file for details.

This project is for educational and research purposes. Please cite the MMRF CoMMpass study appropriately when using these methods or findings.

---

*Last Updated: January 30, 2026*  
*Current Version: 2.0 (Phase 2 Complete)*  
*Next Milestone: RNA-seq Integration (Phase 3)*
